Advicenne (Euronext: ADVIC – FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric therapeutic products for the treatment of orphan diseases, today announced its intention to list its shares on the regulated market of Euronext Brussels.

The ordinary shares of Advicenne are currently listed on the Euronext Paris stock exchange and would also be admitted to trading on Euronext Brussels as part of the proposed secondary listing. The company would thus benefit from a cross listing on the two largest Euronext markets for companies in the life sciences sector. The cross listing would have no impact on current shareholders and Euronext Paris remains Advicenne’s primary listing venue.